National Bank of Canada
CMPX icon

National Bank of Canada’s Compass Therapeutics CMPX Stock Holding History

National Bank of Canada’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.24K Sell
235
-7
-3% -$40 ﹤0.01% 2658
2025
Q4 		$1.3K Buy
+242
New +$1.12K ﹤0.01% 2606

Other funds holding CMPX

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

National Bank of Canada's CMPX Position: Q1 2026 in Review

National Bank of Canada reduced its Compass Therapeutics (CMPX) stake by 2.9% in Q1 2026, selling an estimated $40 and leaving 235 shares worth $1.24K. The position accounts for ﹤0.01% of the portfolio, ranked #2658.

National Bank of Canada first reported a position in CMPX in Q4 2025 and has held it in 2 quarters since. The position peaked at $1.3K in Q4 2025. 201 funds tracked by Wall St. Rank hold CMPX as of Q1 2026.

  • National Bank of Canada held 235 shares of Compass Therapeutics worth $1.24K as of Q1 2026.
  • National Bank of Canada sold 7 Compass Therapeutics shares in Q1 2026, an estimated $40.
  • Compass Therapeutics made up ﹤0.01% of National Bank of Canada's portfolio in Q1 2026, its #2658 holding.
  • National Bank of Canada first reported a position in Compass Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • National Bank of Canada's Compass Therapeutics position peaked at $1.3K in Q4 2025.
  • 201 funds tracked by Wall St. Rank held Compass Therapeutics as of Q1 2026.

Based on National Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.